An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Published
Journal Article
© 2015 Elsevier Ltd. New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
Full Text
Duke Authors
Cited Authors
- Lin, J; Deng, A; Hoffman-Censits, J; Gibney, G; Hyslop, T; Miller, B; Kilpatrick, D; Jabbour, S; Kevin Kelly, W
Published Date
- January 1, 2015
Published In
Volume / Issue
- 4 /
Start / End Page
- 192 - 195
International Standard Serial Number (ISSN)
- 2213-0896
Digital Object Identifier (DOI)
- 10.1016/j.ctrc.2015.11.003
Citation Source
- Scopus